Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPX-113 is an allogeneic cell therapy consisting of cultured mucosal cells, currently under development by Tego Science. It is designed for the treatment of oral mucosal defects, aiming to facilitate the repair and regeneration of damaged oral tissues. As an allogeneic product, TPX-113 utilizes cells derived from a donor rather than the patient, which allows for standardized manufacturing and potential "off-the-shelf" clinical availability. This distinguishes it from autologous therapies, such as TPX-112, which require patient-specific cell harvesting. TPX-113 is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TPX-113.